At present, relatively high dosages of haloperidol (or equivalent dosages of other neuroleptics) of around 15 mg are frequently used in our clinic for the treatment of an acute schizophrenic episode or an exacerbation. During chronic maintenance treatment, however, the mean range lies somewhere between 1.5 and 6 mg daily of haloperidol, often in combination with a mild daily dosage of a sedative neuroleptic.
At present, relatively high dosages of haloperidol (or equivalent dosages of other neuroleptics) of around 15 mg are frequently used in our clinic for the treatment of an acute schizophrenic episode or an exacerbation. During chronic maintenance treatment, however, the mean range lies somewhere between 1.5 and 6 mg daily of haloperidol, often in combination with a mild daily dosage of a sedative neuroleptic.
The results described by Howard & Schmidt (1973) with a rapidly increasing and higher than usual dosage scheme of haloperidol in back ward schizophrenic patients, are so strikingly favourable that we decided to set up a study with the same dosage scheme, i.e. a starting dose of 15 mg weekly, increased by 7.5 mg to a maximum of 75 mg for not longer than five months. In order to see whether we could obtain similar results in our setting and with our patient material, our main target was to see how many patients would be improved to the point of being ready for discharge from the mental hospital.
Patients and Methods
Thirty-eight patients were selected from a group of chronic schizophrenic patients who had already been hospitalized for several years and for whom any hope for remission that would permit discharge (or even a mere amelioration) had been abandoned. They were receiving maintenance treatment, generally with a moderate dosage of one or more antipsychotic drugs, together with the usual type of group and occupational therapy currently given at this hospital. This patient population was divided into two groups, distributed more or less equally among different wards. In only one group was a simultaneous programme of group therapy instituted together with the drug regime in imitation of the group-motivational procedure as utilized in the study of Howard & Schmidt. These groups will be referred to as group A (with) and group B (without) group therapy. Eighteen of the 38 patients in this study were considered potential candidates for effective group therapy. Thus, at the start group A contained 18 and group B 20 patients. Routine combined drug medication was slowly reduced to nothing and replaced by The daily starting dose was 15 mg, to be increased weekly by 7.5 mg until either: (1) marked amelioration (suitability for discharge) was observed; or (2) incapacitating extrapyramidal effects occurred, which failed to respond sufficiently to corrective therapy; or (3) the maximum dose of 75 mg daily had been obtained. Whenever possible, this dose was administered until the end of the study.
The total duration of the study was five months. As concomitant medication anti-parkinsonian agents and/or a sedative neuroleptic were allowed, the latter if pronounced agitation, anxiety or insomnia were observed.
Evaluation Methods
Before and after one, three and five months of treatment the factor construct rating scale (FCRS: Overall 1964) and a discharge readiness questionnaire (DRQ) were completed by one and the same psychologist for all patients. At monthly intervals the occupational therapists completed a rating scale, as did the group therapist in Group A.
A global assessment, including evaluation of psychiatric status and readiness for discharge, was made by the chief psychiatrist at the end of the study with the aim of classifying the patients as clearly improved or not. The safety evaluation included complete blood counts and standard biochemistry (blood urea nitrogen, blood sugar, bilirubin, alkaline phosphatase, SGOT, SGPT), urinalysis, EEG and ECG before and after three and five months of treatment. Heart-rate, blood pressure and weight were checked monthly.
Results
During the study, one patient of group A proved to be unsuited for group therapy and was switched to group B while 3 patients in group B improved sufficiently to be moved to group A. After one month the group A comprised 20 and group B 18 patients. Tables I and 2 give the results of the global psychiatric evaluation at the termination of this study. From these figures it appears that 23 patients (61 %) markedly or moderately improved, although any hope of a remission had been abandoned. We have to stress that 4 of these patients could be considered as cured and that 19 patients improved in their relational life in the institute.
All group A patients, but only 11 group B patients completed the study. Seven patients from the B group were considered as drop-outs due to maladjustment to the experimental drugdosage scheme. Four drop-outs were not drugrelated and 3 were induced respectively by a considerable weight loss, excessive sedation, and hyperpyrexia associated with asthenia. In these drop-outs, the pre-study haloperidol dosage was reinstituted and the patients were further clinically followed and globally evaluated at the end of the study ( Table 1 ). The results of this final global evaluation showed that 4 patients improved markedly and 19 moderately. Although not rated as being improved, all 15 other patients showed some increase in psychomotor alertness and initiative, according to the nurse's judgment. The nursing personnel noted that there was more and better contact with the treated patients. FCRS= No. of scores > 2(2 =mild; 1-7 =absent to very pronounced) DRQ (5 clusters) (increasing normality 1-8 or 9-11, possible total score = 46) Occupational therapy (4 items) (increasing normality 1-5) Group therapy (good to excellent participation/No. of participating patients) Dosage of haloperidol (mg/day) Evaluation tests:
FCRS-No. of scores >2(2 =mild; 1-7 = absent to very pronounced) DRQ (5 clusters) (increasing normality 1-8 or 9-1, possible total score =46) Occupational therapy (4 items The psychiatrists generally felt that because of haloperidol alone the patients became less bold and more human. They were less withdrawn and showed more mimicry in their faces. The improvements according to the scales were moderate and there was little difference between successes and failures in the A group, while in the B group the improvement of DRQ and occupational therapy was better in the successful patients. The latter also eventually reached higher dose levels.
From analysis of patient records we noticed that the favourable results were evenly distributed over the different dosage profiles, underlining the necessity for an individually adapted dosage schedule. The safety evaluation studies in the laboratory during and at the end of the treatment did not show any significant changes and confirm the relative safety of haloperidol in dosages which are higher than usual. Another surprising aspect that appeared from this study is the finding that very often one neuroleptic (here haloperidol) sometimes given together with an anti-parkinsonian agent was sufficient for adequate treatment of the patient. Fig 1 shows the reduction in polypharmacy when adequate individual dosages of haloperidol are administered. In 17 patients two or more drugs could be abandoned. Most commonly prescribed antipsychotics before the trial were thioproperazine; haloperidol; levomepromazine; clopenthixol; phenobarbital; thioridazine and thiothixene. The most commonly used antiparkinsonian agent in our hospital was dexetimide (De Smedt et al. 1970 , Janssen et al. 1971 , Korn et al. 1971 , Huygens et al. 1973 ).
Discussion
There is increasing evidence that the maintenance of patients on the lowest possible dose of a combination of neuroleptics is a principle that should be abandoned because it leads to unpractical and uneconomical polypharmacy. This principle should also be abandoned for therapeutic reasons. Indeed, in our study over half of the chronic psychotic patients improved when switched from a 'cocktail' of neuroleptic drugs in low dosage to a drug regimen of adequate individualized dosages of haloperidol combined, when necessary, with a sedative or an antiparkinsonian agent. Adequate individual dosage often means higher dosage and therefore extrapyramidal symptoms. However, this seems to occur only in a certain dosage range. When necessary, one should give a dosage which surpasses this range to overcome such extrapyramidal effects.
As soon as clinical improvement is apparent the dosage will be reduced to a level which is optimal for the control of the psychotic symptoms for that patient. This dosage will generally be a few times the original dose.
Suimmary
The effect of higher than usual dosages of haloperidol was studied in 38 chronic institutionalized schizophrenic patients for whom any hope of discharge had been abandoned. In 23 patients (61 %) a marked or moderate improvement was observed. No striking differences were seen between patients simultaneously receiving or not receiving group therapy. The 15 remaining patients put on haloperidol alone showed some increase in psychomotor alertness, according to the nurses' judgment. It is clear from these results that higher than usual dosages of haloperidol can be safely administered and can be of considerable value in chronic institutionalized schizophrenic patients.
